To include your compound in the COVID-19 Resource Center, submit it here.

IMGN901 lorvotuzumab mertansine: Additional Phase I data

Additional data from the ongoing, open-label, dose-escalation, U.S. Phase I Study 005 trial in 13 evaluable patients showed that IV IMGN901 plus lenalidomide and

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE